Affiliation:
1. Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy
2. Tianjin University of Traditional Chinese Medicine
Abstract
Abstract
Background
Different programmed cell death (PCD) plays different roles in lung squamous cell carcinoma (LUSC). We integrated twelve programmed cell death patterns, investigated the expression patterns of PCD-related genes to identify promising PCD-related biomarkers.
Methods
Twelve PCD patterns (apoptosis, pyroptosis, necroptosis, cuproptosis, entotic cell death, autophagy-dependent cell death, netotic cell death, parthanatos, ferroptosis, lysosome-dependent cell death, oxeiptosis and alkaliptosis) were analyzed for model construction, resulting in 1388 PCD-related genes. We explored the expression changes of PCD-related genes in LUSC patients from TCGA database, and constructed a combined prognostic signature by Cox regression analysis and LASSO Cox regression analysis. The independent prognostic performance of the gene signature was evaluate based on consensus clustering, univariate and multivariate Cox regression and Kaplan–Meier survival. The GEO dataset was used for validation. Finally, we investigated the role of the immune microenvironment in different prognosis groups.
Results
We constructed a network of seven PCD-related genes (FGA, CHEK2, PTGIS, CSF2, STXBP1, NACC2, TFR2). Utilized these 7-gene network to establish a cell death index (CDI) and grouped patients using the median of CDI. We found that LUSC patients with low CDI had a better prognosis. More importantly, CDI was associated with tumor microenvironment components according to integrated analysis, and the response to immunotherapy in the low CDI group was better than that in the high CDI group.
Conclusion
Our study identified 7-gene network based on PCD to establish a new model of CDI to predict the clinical prognosis of LUSC patients. We proposed that CDI may serve as a new biomarker to predict the prognosis and immunotherapy efficacy in LUSC.
Publisher
Research Square Platform LLC